Compare INGN & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | KRRO |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 187.9M |
| IPO Year | 2013 | 2019 |
| Metric | INGN | KRRO |
|---|---|---|
| Price | $5.56 | $13.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $11.25 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 230.4K | 92.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,668,000.00 | $6,392,000.00 |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.86 | ★ 181.46 |
| 52 Week Low | $5.34 | $5.20 |
| 52 Week High | $9.13 | $55.89 |
| Indicator | INGN | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 59.88 |
| Support Level | $5.48 | $9.76 |
| Resistance Level | $6.73 | $14.45 |
| Average True Range (ATR) | 0.20 | 0.78 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 6.48 | 82.71 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.